Trial Profile
An Open-Label, Phase 1B Study of NEO-PV-01 With Pembrolizumab Plus Chemotherapy in Patients With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Sep 2022
Price :
$35
*
At a glance
- Drugs NEO-PV 01 (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Pemetrexed; Poly ICLC
- Indications Carcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors BioNTech; Neon Therapeutics
- 12 Sep 2022 Results of an analysis of the clinical and immune data published in the Cancer Cell
- 10 Apr 2021 Results presented at the 112th Annual Meeting of the American Association for Cancer Research
- 24 Feb 2021 Status changed from active, no longer recruiting to completed.